Bayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class example from Leverkusen. Whether the data will be sufficient for regulatory approval remains to be seen.
ADVERTISEMENT
Tag Archive for: Heart
Semaglutide (Ozempic®) and Tirzepatide (Mounjaro®) not only promote weight loss but also significantly reduce the risk of major cardiovascular events in patients with type 2 diabetes. Real-world evidence from the Technical University of Munich and Harvard Medical School shows up to 18% lower risk of heart attack and stroke, highlighting the growing potential of GLP-1 therapies in cardiometabolic care.
Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
Andera Partners, Paris based European private equity player, announced on Wednesday that, together with RA Capital Management, it is leading an oversubscribed and up-sized $118m Series B financing for Mineralys Therapeutics, Inc., Philadelphia (USA), a private, clinical-stage biopharmaceutical company developing novel therapy for the treatment of hypertension.


© Bayer Leverkusen
Adobe stock photos - Dzmitry 

Pixabay.com